Andrew J. Robertson
- P: 604.631.9131
- F: 604.669.1620
- Amanda Jamieson
- Legal Assistant
- P: 604.408.5447
Andrew practices corporate and securities law and has experience in a variety of transactions, including share and asset acquisitions, corporate reorganizations, public offerings, and various other corporate proceedings. Andrew works with both public and private companies.
Prior to joining Lawson Lundell, Andrew articled in the Toronto office of an international law firm, and later worked as an associate at a boutique Toronto business law firm.
- Canadian Bar Association, Member
- Canadian Bar Association, Securities Law Subsection, Member
- Andrew is the Corporate Secretary & Legal Advisor to S-Drive, a not-for-profit organization dedicated to the personal and professional development of young professionals through networking, philanthropy and community engagement.
- British Columbia (2014)
- Ontario (2013)
- University of Toronto, (J.D., 2012)
- Simon Fraser University (B.A., 2009)
- Completed Level 1 of the Chartered Financial Analyst Program (2014)
Andrew enjoys golfing and playing soccer. He has been interested and involved in politics since high school. In 2008, Andrew ran as a candidate for municipal council.
- Advised Highland West Capital in its partnership arrangements with AllWest Insurance Services Ltd.
- Acted for a gold mining company in the public offering of US$100,000,000 of common shares on the TSX and the NYSE MKT.
- Advised numerous companies in relation to seed, Series A, and bridge financings.
- Represented Ritchie Bros. Auctioneers Incorporated (Ritchie Bros.), in acquiring the remaining 49% interest in Ritchie Bros. Financial Services Ltd. (RBFS) from a minority shareholder group. The transaction involved cash consideration of $53.9 million, together with additional compensation that may be payable to the vendor, contingent upon certain operating performance targets being achieved over the next three years.
- Advising OnCore BioPharma on Canadian matters in its announced merger with Tekmira Pharmaceuticals. Under the announced terms of the merger, valued at $US 750 million, OnCore will merge with a wholly-owned subsidiary of Tekmira and will become a wholly-owned subsidiary of Tekmira. Upon completion, OnCore shareholders will hold approximately 50% of the total number of outstanding shares of Tekmira on a fully-diluted, as converted basis.
- The importance of tying executive compensation to performance,The Northern Miner(March 23, 2015),Co-Author
- The Northern Miner(March 2, 2015),Co-author